oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2019-18-6-75-81oncotomsk-1246Research ArticleЛАБОРАТОРНЫЕ И ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯLABORATORY AND EXPERIMENTAL STUDIESМОДЕЛИРОВАНИЕ ИНТЕРНАЛИЗАЦИИ ВОДОРАСТВОРИМЫХ ПРОТИВООПУХОЛЕВЫХ ЦИТОСТАТИКОВ В ТОНКОЙ КИШКЕ ЭКСПРЕСС-МЕТОДОМ EX VIVO С ПОМОЩЬЮ ХЕМИЛЮМИНЕСЦЕНЦИИMODELING OF EX VIVO INTERNALIZATION METHOD OF WATER- SOLUBLE ANTICANCER DRUGS IN SMALL INTESTINE USING CHEMILUMINESCENCEhttps://orcid.org/0000-0002-3878-3958ТрещалинаЕ. М.TreshalinaH. M.

24, Kashirskoye shosse, 115548-Moscow, Russia

treshalina@yandex.ruhttps://orcid.org/0000-0003-3193-4685ЧеркасоваЖ. Р.AndronovaN. V.

кандидат медицинских наук, старший научный сотрудник лаборатории радионуклидных и лучевых технологий в экспериментальной онкологии

Россия, г. Москва, 143026, ИЦ Сколково, Б. Бульвар, 42

PhD, Researcher, Laboratory of Radionuclide and Radiation Technologies in Experimental Oncology

24, Kashirskoye shosse, 115548-Moscow, Russia

https://orcid.org/0000-0002-0030-1802АндроноваН. В.TcherkassovaJ. R.

PhD

B. Boulevard 42, 143026-Moscow, Russia

ЛукашеваЕ. В.KlinskiE. Yu.

доктор биологических наук, профессор кафедры биохимии им. акад. Т.Т. Березова, Медицинскийинститут

ORCID: 0000-0003-1029-5770 Россия, г. Москва, 117198, ул. Миклухо-Маклая, 6

PhD, Head of the Laboratory of Markers and New Methods of Tumor Diagnostics

B. Boulevard 42, 143026-Moscow, Russia

https://orcid.org/0000-0001-5781-7925БабаеваГ.BabayevaG.

Postgraduate, Department of Biochemistry n.m. of Acad. T.T. Berezov, Medical Institute

6, Miklukho-Maklaya street, 117198-Moscow, Russia  

https://orcid.org/0000-0002-0030-1802КлинскийЕ. Ю.LukashevaE. V.

Professor, Department of Biochemistry n.m. of Acad. T.T. Berezov, Medical Institute

ORCID: 0000-0003-1029-5770

6, Miklukho-Maklaya street, 117198-Moscow, Russia

https://orcid.org/0000-0002-5652-8686ТрещалинМ. И.TreshchalinM. I.

старший научный сотрудник лаборатории химиотерапии и фармакологии

Россия, г. Москва, 119021, ул. Б. Пироговская, 11

Researcher, Laboratory of Chemotherapy and Pharmacology

11, Pirogovskaya street, 119021-Moscow, Russia

https://orcid.org/0000-0002-0030-1802ЦурканС. А.TsurkanS. A.

PhD, Leading Researcher, Laboratory of Tumor Markers and New Methods of Diagnosis of Tumors

B. Boulevard 42, 143026-Moscow, Russia 

ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииРоссияN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaRussian FederationООО «Джейвис Диагностикс»РоссияN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaRussian FederationФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииРоссияJVS Diagnostics LLCRussian FederationРоссийский Университет Дружбы народов (РУДН)Россия«JVS Diagnostics LLC» Skolkovo Innovation CenterRussian FederationРоссийский Университет Дружбы народов (РУДН)РоссияPeoples’ Friendship University of RussiaRussian FederationООО «Джейвис Диагностикс»РоссияPeoples’ Friendship University of RussiaRussian FederationФГБНУ «Научно-исследовательский институт по изысканию новых антибиотиков им. Г.Ф. Гаузе»РоссияGause Institute of New AntibioticsRussian FederationООО «Джейвис Диагностикс»Россия«JVS Diagnostics LLC» Skolkovo Innovation CenterRussian Federation2019050120201867581Copyright © Трещалина Е.М., Черкасова Ж.Р., Андронова Н.В., Лукашева Е.В., Бабаева Г., Клинский Е.Ю., Трещалин М.И., Цуркан С.А., 20202020Трещалина Е.М., Черкасова Ж.Р., Андронова Н.В., Лукашева Е.В., Бабаева Г., Клинский Е.Ю., Трещалин М.И., Цуркан С.А.Treshalina H.M., Andronova N.V., Tcherkassova J.R., Klinski E.Y., Babayeva G., Lukasheva E.V., Treshchalin M.I., Tsurkan S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/1246цитостатикиинтернализациятонкая кишкаэкспресс-методex vivocytostaticsinternalizationrat small intestineexpress-methodex vivoReferencesYan S., L. Yang., Lu L., Guo Q., Hu X., Yuan Y., Li Y., Wu M., Zang J. Improved pharmacokinetic characteristics and bioactive effects of anticancer enzyme delivery systems. Expert opinion on drug metabolism and toxicology. 2018; 14: 951–960. doi: 10.1080/17425255.2018.1505863.Yan S., L. Yang., Lu L., Guo Q., Hu X., Yuan Y., Li Y., Wu M., Zang J. Improved pharmacokinetic characteristics and bioactive effects of anticancer enzyme delivery systems. Expert opinion on drug metabolism and toxicology. 2018; 14: 951–960. doi: 10.1080/17425255.2018.1505863.Mazzaferro S., Bouchemal K., Ponchel G. Oral delivery of anticancer drugs I: general considerations. Drug Discov Today. 2013 Jan; 18(1–2): 25–34. doi: 10.1016/j.drudis.2012.08.004.Mazzaferro S., Bouchemal K., Ponchel G. Oral delivery of anticancer drugs I: general considerations. Drug Discov Today. 2013 Jan; 18(1–2): 25–34. doi: 10.1016/j.drudis.2012.08.004.Sparreboom A., De Jonge M. J. A., Verweij J. The use of oral cytotoxic and cytostatic drugs in cancer treatment. Eur J Cancer. 2002; 38: 1822. doi: 10.1016/S0959-8049(01)00322-7.Sparreboom A., De Jonge M. J. A., Verweij J. The use of oral cytotoxic and cytostatic drugs in cancer treatment. Eur J Cancer. 2002; 38: 1822. doi: 10.1016/S0959-8049(01)00322-7.Андронова Н.В., Черкасова Ж.Р., Цуркан С.А., Смирнова Г.Б., Трещалина Е.М. Оценка интернализации АФП-содержащего нековалентного комплекса Аимпила в модели изолированного отрезка тонкой кишки крыс. Российский онкологический журнал. 2016; 21(6): 308–311. doi: 10.18821/1028-9984-2016-21-6-308-311.Andronova N.B., Tcherkassova J.R., Tsurkan S.A., Smirnova G.B., Treshalina H.M. Evaluation of the internalization of AFP-containing noncovalent complexes AIMPILA in the rat model of the isolated segment of rat small intestine. Russian Journal of Oncology 2016; 21 (6): 308–311.(in Russian). doi: 10.18821/1028-9984-2016-21-6-308-311.Tcherkassova J., Abramovich C., Moro R., Chen C., Schmit R., Gerber A., Moro R. Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer. Tumour Biol. 2011 Aug; 32(4): 831–8. doi: 10.1007/s13277-011-0186-1.Tcherkassova J., Abramovich C., Moro R., Chen C., Schmit R., Gerber A., Moro R. Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer. Tumour Biol. 2011 Aug; 32(4): 831–8. doi: 10.1007/s13277-011-0186-1.Réti-Nagy K., Malanga M., Fenyves E., Szente L., Vámosi G., Váradi J., Bácskay I., Fehér P., Ujhelyi Z., Róka E., Vecsernyés M., Balogh G., Vasvári G., Fenyvesi F. Endocytosis of fluorescent cyclodextrins by intestinal Caco-2 cells and its role in paclitaxel drug delivery. Int J Pharm. 2015 Dec 30; 496(2): 509–17. doi: 10.1016/j.ijpharm.2015.10.049.Réti-Nagy K., Malanga M., Fenyves E., Szente L., Vámosi G., Váradi J., Bácskay I., Fehér P., Ujhelyi Z., Róka E., Vecsernyés M., Balogh G., Vasvári G., Fenyvesi F. Endocytosis of fluorescent cyclodextrins by intestinal Caco-2 cells and its role in paclitaxel drug delivery. Int J Pharm. 2015 Dec 30; 496(2): 509–17. doi: 10.1016/j.ijpharm.2015.10.049.Tsurkan S., Tcherkassova J., Gorbunova V., Treshalina H. New drug AIMPILA targeted to AFP receptor: Oral anticancer therapy and biodistribution in vivo. J Clin Oncol. 2018: 36 (15_suppl): e24232–24232. doi: 10.1200/JCO.2018.36.15.Tsurkan S., Tcherkassova J., Gorbunova V., Treshalina H. New drug AIMPILA targeted to AFP receptor: Oral anticancer therapy and biodistribution in vivo. J Clin Oncol. 2018: 36 (15_suppl): e24232–24232. doi: 10.1200/JCO.2018.36.15.Pokrovsky V.S., Treshalina H.M., Lukasheva E.V., Sedakova L.A., Medentzev A.G., Arinbasarova A.Yu., Berezov T.T. Enzymatic properties and anticancer activity of L-lysine alpha-oxidase from Trichoderma cf. aureoviride Rifai ВКМF-4268D. Anticancer Drugs. 2013 Sep; 8(24): 846–851. doi: 10.1097/CAD.0b013e328362fbe2.Pokrovsky V.S., Treshalina H.M., Lukasheva E.V., Sedakova L.A., Medentzev A.G., Arinbasarova A.Yu., Berezov T.T. Enzymatic properties and anticancer activity of L-lysine alpha-oxidase from Trichoderma cf. aureoviride Rifai ВКМF-4268D. Anticancer Drugs. 2013 Sep; 8(24): 846–851. doi: 10.1097/CAD.0b013e328362fbe2.Покровский В.С., Трещалина Е.М., Лукашева Е.В., Седакова Л.А. Разработка режима внутривенного введения лизин-альфа-оксидазы из Trichoderma cf. aureoviride Rifai вкmf-4268 под контролем переносимости и эффективности лечения. Российский онкологический журнал. 2013; 2: 10–14.Pokrovsky V.S., Treshalina Е.M., Lukasheva E.V., Sedakova L.A. Development of intravenous administration of L-lysinealpha-oxidase from Trichoderma CF. Aureoviride Rifai BKMF-4268 regime controlled by safety and efficacy of treatment. Russian Journal of Oncology. 2013; 2: 10–14. (in Russian).Kusakabe H., Kodama K., Kuninaka F., Yoshino Y., Misono H., Soda K. A new antitumor enzyme, L-lysine alpha-oxidase from Trichoderma viride. Purification and enzymological properties. J Biol Chem. 1980. 255: 976–981.Kusakabe H., Kodama K., Kuninaka F., Yoshino Y., Misono H., Soda K. A new antitumor enzyme, L-lysine alpha-oxidase from Trichoderma viride. Purification and enzymological properties. J Biol Chem. 1980. 255: 976–981.Lukasheva E.V., Ribakova Y.S., Fedorova T.N., Makletsova M.G., Arinbasarova A.Y., Medentzev A.G., Berezov T.T. Isolation and properties of L-Lysine α-oxidase from Trichoderma cf. aureoviride Rifai ВКМ F-4268D. Microbiologia. 2012; 81: 594–594. doi: 10.1134/S0026261712050037.Lukasheva E.V., Ribakova Y.S., Fedorova T.N., Makletsova M.G., Arinbasarova A.Y., Medentzev A.G., Berezov T.T. Isolation and properties of L-Lysine α-oxidase from Trichoderma cf. aureoviride Rifai ВКМ F-4268D. Microbiologia. 2012; 81: 594–594. doi: 10.1134/S0026261712050037.Asano Y., Yasukawa K. Identification and development of amino acid oxidases. Curr Opin Chem Biol. 2019 Apr; 49: 76–83. doi: 10.1016/j.cbpa.2018.10.020.Asano Y., Yasukawa K. Identification and development of amino acid oxidases. Curr Opin Chem Biol. 2019 Apr; 49: 76–83. doi: 10.1016/j.cbpa.2018.10.020.Щекотихин А.Е., Трещалина Е.М., Трещалин И.Д. Пероральные противоопухолевые агенты и метод лечения рака. Патент РФ № 2639479. 2017.Shchekotikhin A.E., Treshalina H.M., Treschalin I.D. Oral anticancer agents and method of treatment of cancer. Russian patent № 2639479. 2017. (In Russian).Treshalina H.M., Romanenko V.I., Kaluzhny D.N., Treshalin M.I., Nikitin A.A., Tikhomirov A.S., Shchekotikhin A.E. Development and pharmaceutical evaluation of the anticancer Anthrafuran/Cavitron complex, a prototypic parenteral drug formulation. Eur J Pharm Sci. 2017 Nov 15; 109: 631–637. doi: 10.1016/j.ejps.2017.09.025.Treshalina H.M., Romanenko V.I., Kaluzhny D.N., Treshalin M.I., Nikitin A.A., Tikhomirov A.S., Shchekotikhin A.E. Development and pharmaceutical evaluation of the anticancer Anthrafuran/Cavitron complex, a prototypic parenteral drug formulation. Eur J Pharm Sci. 2017 Nov 15; 109: 631–637. doi: 10.1016/j.ejps.2017.09.025.Tikhomirov A.S., Lin C.Y., Volodina Y.L., Dezhenkova L.G., Tatarskiy V.V., Schols D., Shtil A.A., Punit Kaur, Pin Ju Chueh, Shchekotikhin A.E. New antitumor anthra [2, 3-b] furan-3-carboxamides: Synthesis and structure-activity relationship. Eur J Med Chem. 2018 Mar 25; 148: 128–139. doi: 10.1016/j.ejmech.2018.02.027.Tikhomirov A.S., Lin C.Y., Volodina Y.L., Dezhenkova L.G., Tatarskiy V.V., Schols D., Shtil A.A., Punit Kaur, Pin Ju Chueh, Shchekotikhin A.E. New antitumor anthra [2, 3-b] furan-3-carboxamides: Synthesis and structure-activity relationship. Eur J Med Chem. 2018 Mar 25; 148: 128–139. doi: 10.1016/j.ejmech.2018.02.027.Заведос. Лекарственный справочник ГЭОТАР [Интернет]. URL: https://www.lsgeotar.ru/zavedos-3422.html. (дата обращения: 16.04.2019).Zavedos. Medicinal guide GEOTAR [Internet]. URL: https://www.lsgeotar.ru/zavedos-3422.html. (cited: 16.04.2019). (in Russian).Amin M., Pourshohodb A., Kheirollahb A., Afrakhtehb M., Gholami-Borujenic F., Zeinalid M., Jamalanef M. Specific delivery of idarubicin to HER2-positive breast cancerous cell line by trastuzumabconjugated liposomes. J Drug Delivery Sci Technol. 2018; 47: 209–214. doi: 10.1016/j.jddst.2018.07.017.Amin M., Pourshohodb A., Kheirollahb A., Afrakhtehb M., Gholami-Borujenic F., Zeinalid M., Jamalanef M. Specific delivery of idarubicin to HER2-positive breast cancerous cell line by trastuzumabconjugated liposomes. J Drug Delivery Sci Technol. 2018; 47: 209–214. doi: 10.1016/j.jddst.2018.07.017

The authors declare that there are no conflicts of interest present.